Rare Disease · In-Market · Updated August 2026
A one-time therapy cannot be forecast like a recurring one. Every patient treated leaves the pool permanently, so revenue is front-loaded and finite by construction.
Newborn screening changed the shape of this market. It moved diagnosis ahead of symptom onset, which both expanded the treatable population and compressed the window in which a treatment decision is made. Sizing has to separate total prevalence from the screened, diagnosed and treated pools, because the gaps between them are where the commercial variables sit.
Gene therapy has to be modelled as a depletion curve rather than a revenue run-rate. An initial catch-up wave clears the prevalent backlog, after which volume falls to the incident birth rate. A model that extrapolates the catch-up period forward will overstate the franchise by a wide margin, and the timing of the inflection matters more to a business case than the peak figure does.
Net price, not list price, is the number that matters. A widening share of volume is paid through outcomes-based arrangements and milestone-linked annuities rather than as a single payment, so a growing proportion of patients never pay the headline figure. Modelling on list price will misstate both revenue and its timing.
With three modalities and no head-to-head trial, share cannot be read off efficacy. It follows the treatment-decision algorithm by patient type and route of administration, which is where the model has to be built.
AXLRx SMA reports size the screening funnel across the US, UK and Gulf and model the depletion curve on net price. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
For the wider context, see orphan drug approvals in numbers: FDA and EMA orphan approvals counted by year, condition and sponsor.
SMA affects an estimated 8,000-10,000 US patients at an incidence near 1 in 10,000 live births, roughly 98% caused by biallelic SMN1 loss. GCC incidence runs higher at 1:6,000-8,000, elevated by consanguinity, producing about 300-350 new cases a year. Identification is now screening-driven: SMA joined the US Recommended Uniform Screening Panel in 2018 and all 50 states screen by 2023, catching about 300 pre-symptomatic infants a year. The UK launched the first national European programme in 2021, while GCC coverage ranges from about 90% in Saudi Arabia to under 50% in Oman, Bahrain, and Kuwait.
Newborn screening detects homozygous SMN1 deletion from a dried blood spot, then confirmatory genetic testing measures SMN1 and SMN2 copy number. SMN2 copy number sets severity across the Type 1-4 clinical spectrum, since the paralogous SMN2 gene makes a small amount of functional SMN protein. This splits the population into two commercially distinct cohorts: pre-symptomatic screening-identified infants and older symptomatic patients. Adult-onset Type 4 SMA sits outside the screening funnel, frequently misdiagnosed as limb-girdle muscular dystrophy or ALS before SMN1/SMN2 testing confirms it.
Three FDA-approved agents address the same SMN deficit by different routes. Nusinersen (Spinraza, Biogen), approved December 2016, is an intrathecal antisense oligonucleotide that modifies SMN2 splicing, with 41% motor-milestone responders versus 0% control in ENDEAR. Onasemnogene abeparvovec (Zolgensma, Novartis Gene Therapies), approved May 2019 for patients under two, is a one-time AAV9 gene therapy priced at $2.125M list, showing 91% event-free survival at 14 months in STR1VE. Risdiplam (Evrysdi, Roche/PTC Therapeutics), approved August 2020 for all ages, is a daily oral SMN2 modifier studied in FIREFISH.
We split the population before sizing it. The prevalent pool, an estimated 8,000-10,000 US patients across Types 1-4, is finite and depletes as one-time gene therapy treats it. The incident flow is what newborn screening governs: about 300 pre-symptomatic US infants a year, but only where coverage reaches them. Addressable volume therefore tracks screening penetration by geography, not raw incidence, running from roughly 90% in Saudi Arabia to under 50% in Oman, Bahrain, and Kuwait. We model each geography off its own coverage curve, run a coverage-sensitivity band, then layer a three-modality share split over the incident cohort and a depletion curve over the prevalent pool. Legacy pre-screening Type 2/3 adults, 800-1,200 in the GCC, size separately as chronic-therapy volume.
No trial compares intrathecal nusinersen, one-time Zolgensma, and oral risdiplam directly, so share cannot be read off efficacy. We model it off the treatment-decision algorithm by patient type and route preference. Pre-symptomatic screening-identified infants under two route to gene therapy, where near-normal motor development is achievable. Symptomatic Type 2/3 patients choose between intrathecal and oral, where oral risdiplam has taken roughly 50% of pediatric starts on convenience, while nusinersen retains established patients but loses new starts. We sequence share by segment and by new-start-versus-switch dynamics, then stress the split against screening timing, since earlier identification pulls more volume into the gene-therapy branch. Adult Type 4 sits outside all three algorithms.
A one-time therapy cannot be modelled like a recurring drug, because each patient treated leaves the pool permanently. We build Zolgensma volume as a depletion curve: an initial catch-up wave clearing the prevalent Type 1 backlog, then a settle to the incident birth-cohort rate that newborn screening feeds. As the backlog clears, the treatable pool shifts almost entirely to pre-symptomatic screening-identified infants under two, so long-run volume equals screened births times coverage times genetic penetrance, not prevalence. We size the durability tail separately: an estimated 500-700 US children treated between 2019 and 2023, now 4-7 years old, of whom 15-20% show early motor plateau. That attenuation cohort becomes a named addressable segment for boosters or add-on therapy.
We model net price, not list price, because a widening share of volume never pays the $2.125M headline. In the US, ten states pay through a CMS milestone-linked annuity of roughly $212,500 a year for ten years, so we build cash flows as risk-adjusted installments gated on motor milestones, not a single upfront sum. The GCC references the same precedent: a negotiated $1.5-1.8M price with a 24-month motor-milestone rebate. The comparator is cumulative chronic spend, nusinersen near $750,000 in year one then $375,000 a year, or risdiplam about $340,000 a year, so over a ten-year horizon the one-time cost is broadly comparable. We model break-even by milestone-achievement rate and payment duration, since both move the effective net price.
Each answer above draws on a specific AXLRx model. The screening-funnel sizing comes from our SMA market-sizing and patient-flow models across the US, UK, and GCC, which separate total prevalence, screening-identified incidence, and the Zolgensma-treated cohort. The three-modality share logic and the attenuation segment come from our competitive-intelligence and launch-readiness briefs. The contract economics come from our US, UK, and GCC pricing-strategy and payer-HTA models on CGTA annuities, NPHC milestone rebates, and the Long-Term Value Framework, alongside KOL mapping of the designated gene-therapy centres that gate access.